“Trends in immunosuppressive therapy: A report of the North American Pediatric Cooperative Study (NAPRTCS)”, Pediatr Transplantation, vol. 3, pp. 27-32, 1999.,
“A Randomized Multicenter Trial of OKT3 mAbs Induction Compared With Intravenous Cyclosporine in Pediatric Renal Transplantation”, Pediatric Transplantation, vol. 9, pp. 282-292, 2005.,
“Comparative study of the safety, efficacy, and practice patterns of Monoclonal antibodies (MAbs) in pediatric renal transplantation (PRT)”, 2002.,
“Safety of kidney biopsy in pediatric transplantation: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)”, transplantation, vol. 67, pp. 544-47, 1999.,
“The 1997 Annual report of the North American Pediatric Transplant Cooperative Study (NAPRTCS)”, Pediatr Transplantation, vol. 3, no. 2, pp. 152-167, 1999.,
“Efficacy of Vaccination with Live Attenuated, Cold-Adapted, Trivalent, Intranasal Influenza Virus Vaccine Against a Variant (A/Sidney) not Contained in the Vaccine”, J Pediatric, vol. 136, pp. 168-175, 2000.,
“Correlate of Immune Protection Against HSV-1 Genital Disease in Vaccinated Women”, J Infect Dis, vol. 209, pp. 828-836, 2014.,
“Comparative Immunogenicity of Trivalent Influenza Vaccine Administered by Intradermal or Intramuscular Route in Healthy Adults”, Vaccine, vol. 25, pp. 6755-6763, 2007.,
“Efficacy Results of A Trial of A Herpes Simplex Vaccine”, N Engl J Med, vol. 366, no. 1, pp. 34-43, 2012.,
“Immunogenicity of Avian Influenza A/Anhui/01/2005(H5N1) Vaccine with MF59 Adjuvant: A Randomized Clinical Trial”, JAMA, vol. 312, pp. 1420-1428, 2014.,
“Dose-dependent neutralizing-antibody responses to vaccinia”, Journal of Infectious Diseases, vol. 189, pp. 493-7, 2004.,
“Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine”, J Infec Dis, vol. 181, pp. 11133-7, 2000.,
“Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers”, J Infec Dis, vol. 183, pp. 1343-52, 2001.
“The efficacy of live attenuated, cold adapted, trivalent, intranasal, influenza virus vaccine in children”, N Engl J Med, vol. 338, pp. 1405-12, 1998.,
“Progress in HIV-1 Vaccine Development”, in 2nd National Conference on Human Retroviruses and Related Infections, Washington DC, 1995.,
“Potent Induction Immunotherapy Promotes Long-Term Insulin Independence After Islet Transplantation in Type 1 Diabetes”, Am J Transplant, vol. 12, pp. 1576-1583, 2012.,
“Remdesivir for the Treatment of Covid-19 - Preliminary Report.”, N Engl J Med, 2020.,
“Visual Acuity as an Outcome Measure in Clinical Trials of Retinal Diseases”, Ophthalmology, vol. 114, pp. 1804-1809, 2007.,
“HIV-Related Predictors and Outcomes in 275 Liver and/or Kidney Transplant Recipients (oral presentation)”, in International AIDS Society , Rome, Italy, 2011.,
“Ability of Minority Patients to Find Donors from an Ethnically Diverse Cord Blood Bank”, in Annual Meeting of the American Society for Histocompatibility and Immunogenetics, Miami, FL, 2002, vol. 100, p. 640a-641a.,
“Loss of living donor renal allograft survival advantage in children with focal segmental glomerulosclerosis”, Kidney Int., vol. 59, pp. 328-33, 2001.
“Graft loss due to recurrence eliminates the graft survival advantage of living donor (LD) over Cadaveric (CD) renal transplants (Tx) in children with focal segmental glomerulosclerosis (FSGS): A report of the North American Pediatric Transplant Cooperati”, 1999.,
“North American Pediatric Renal Transplant Cooperative Study. Outcome of renal transplantation in adolescents with focal segmental glomerulosclerosis”, Pediatr Transplantation, vol. 6, pp. 488-92, 2002.
“Racial differences in donor source, matching, rejection and outcome in Pediatric renal transplantation (PRT)”, 2002.,